论文部分内容阅读
门静脉高压是肝硬化病人失代偿期的主要临床表现之一,是发生多种致命的常见危险并发症,也是肝硬化病人死亡的主要原因,死亡率可达40%以上,对门脉高压进行积极有效的治疗,可望改善肝硬化病人的预后,提高病人的生存质量。因此,在门脉高压早期即开始持续治疗日益引起广泛重视,改变了过去只有当临床出现并发症时,才对症处理的被动局面,近年来药物治疗门静脉高压已作为一种主要的治疗手段。笔者就目前肝硬化门静脉高压药物治疗进展,综述如下:1 缩血管类药
Portal hypertension is one of the major clinical manifestations of decompensation in patients with cirrhosis, is a common fatal common risk of complications, but also the main cause of death of patients with cirrhosis, the mortality rate of up to 40%, portal hypertension Active and effective treatment is expected to improve the prognosis of patients with liver cirrhosis and improve the quality of life of patients. Therefore, continuous treatment in the early stage of portal hypertension is increasingly aroused widespread attention, changing the passive situation of symptomatic treatment only in the past when clinical complications occurred. In recent years, drug-treated portal hypertension has been used as a major treatment. The author of the current progress of cirrhosis portal hypertension drug treatment, summarized as follows: 1 vasoconstrictic drugs